BMS 830216

Drug Profile

BMS 830216

Alternative Names: BMS-830216

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Obesity therapies
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 Nov 2013 Discontinued - Phase-I/II for Obesity in USA (PO)
  • 30 Jun 2011 Bristol-Myers Squibb completes a phase I/II trial for Obesity in USA (NCT00909766)
  • 16 Jun 2011 Bristol-Myers Squibb completes enrolment in its phase I/II trial for Obesity in USA (NCT00909766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top